Get the Stockscreener App
0.257
3.27%
-0.0087
After Hours:
.25
-0.007
-2.72%
Lyra Therapeutics Inc stock is traded at $0.257, with a volume of 711.23K.
It is down -3.27% in the last 24 hours and down -20.11% over the past month.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
See More
Previous Close:
$0.2657
Open:
$0.2653
24h Volume:
711.23K
Relative Volume:
0.66
Market Cap:
$16.85M
Revenue:
$1.56M
Net Income/Loss:
$-62.68M
P/E Ratio:
-0.1647
EPS:
-1.56
Net Cash Flow:
$-64.35M
1W Performance:
-5.83%
1M Performance:
-20.11%
6M Performance:
-95.87%
1Y Performance:
-93.43%
1-Day Range:
$0.254
$0.269
1-Week Range:
$0.2414
$0.2812
52-Week Range:
$0.2414
$6.79
Lyra Therapeutics Inc Stock (LYRA) Company Profile
Name
Lyra Therapeutics Inc
Sector
Industry
Phone
617-373-4600
Address
480 ARSENAL WAY, WATERTOWN, MA
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-31-23 | Initiated | H.C. Wainwright | Buy |
| May-24-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-26-20 | Initiated | BTIG Research | Buy |
| May-26-20 | Initiated | BofA/Merrill | Buy |
| May-26-20 | Initiated | Jefferies | Buy |
| May-26-20 | Initiated | William Blair | Outperform |
View All
Lyra Therapeutics Inc Stock (LYRA) Latest News
The time has not yet come to remove your chips from the table: Lyra Therapeutics Inc (LYRA) - SETE News
Where Do Analysts Think The Lyra Therapeutics Inc (NASDAQ: LYRA) Is Going - Stocks Register
Lyra Therapeutics Inc (LYRA) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
Lyra Therapeutics to Present Study Results for LYR-210 and - GlobeNewswire
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings - StockTitan
Lyra Therapeutics stock plunges to 52-week low of $0.25 - Investing.com India
Market Recap: Lyell Immunopharma Inc (LYEL)’s Positive Momentum, Closing at 1.46 - The Dwinnex
XTX Topco Ltd Invests $500,000 in Lindsay Co. (NYSE:LNN) - MarketBeat
Great Point Partners LLC Purchases New Position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Defense World
Understanding LXRX’s book value per share for better investment insights - US Post News
All You Need to Know About Tyler Technologies (TYL) Rating Upgrade to Buy - Yahoo Finance
Upward Trajectory: Lexicon Pharmaceuticals Inc (LXRX) Posts a Slidee, Closing at 1.58 - The Dwinnex
Lyell Immunopharma Inc (LYEL)’s stock price in review: A technical analysis - US Post News
Intech Investment Management LLC Buys 1,502 Shares of Tyler Technologies, Inc. (NYSE:TYL) - MarketBeat
Citigroup Acquires Substantial Stake in Syrah Resources - TipRanks
Analysts review Tyler Technologies, Inc.’s rating - Knox Daily
Ratio Examination: Lyra Therapeutics Inc (LYRA)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Tyler Technologies, Inc. (NYSE:TYL) Receives $582.31 Average Target Price from Analysts - MarketBeat
GILD: 3 Biotech Stocks to Watch as FDA Approvals Roll In - StockNews.com
There is no doubt that Lyra Therapeutics Inc (LYRA) ticks all the boxes. - SETE News
Renaissance Technologies LLC Acquires 291,000 Shares of LXP Industrial Trust (NYSE:LXP) - Defense World
Acadian Asset Management LLC Makes New Investment in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Are Lyra Therapeutics Inc (LYRA) shares a good deal now? - US Post News
Ratio Revelations: Lyra Therapeutics Inc (LYRA)’s Financial Metrics in the Spotlight - The Dwinnex
The Psychology of Lyra Therapeutics Inc Inc. (LYRA) Price Performance: Understanding Market Sentiment - The InvestChronicle
Taking the lead: Lyra Therapeutics Inc (LYRA) - SETE News
Lyra Therapeutics Inc (LYRA) stock analysis: A simple moving average approach - US Post News
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Given Consensus Rating of “Hold” by Analysts - Defense World
Lyra Therapeutics Inc (LYRA)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
The growth track for Lyra Therapeutics Inc (LYRA) has changed recently - SETE News
Gaining Ground: Lyra Therapeutics Inc (LYRA) Closes Lower at 0.29, Down -4.01 - The Dwinnex
Is it possible to buy Lyra Therapeutics Inc(LYRA) shares at a good price now? - US Post News
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Short Interest Up 18.6% in August - Defense World
A better buy-in window may exist right now for Lyra Therapeutics Inc (LYRA) - SETE News
Was anything negative for Lyra Therapeutics Inc (LYRA) stock last session? - US Post News
Company’s Banking Stock: Dissecting a 5.19% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Despite Recent Gains, Lyra Therapeutics Insiders Are Still Down US$66k - Simply Wall St
Lyra Therapeutics Insiders Still US$66k Away From Original Investment Value - Yahoo Finance
Sinusitis Market to Exhibit Moderate Growth Rate till - openPR
The LYRA Stock Puzzle: Unraveling Lyra Therapeutics Inc’s Fluctuating Performance - The InvestChronicle
Nothing is Better Than Lyra Therapeutics Inc (LYRA) stock at the moment - SETE News
Lyra Therapeutics Inc (LYRA)’s stock chart: A technical perspective - US Post News
Market Highlights: Lyra Therapeutics Inc (LYRA) Ends on a High Note at 0.30 - The Dwinnex
William Blair Brokers Increase Earnings Estimates for Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Lyra Therapeutics (NASDAQ:LYRA) Rating Reiterated by Cantor Fitzgerald - Defense World
Lyra Therapeutics (NASDAQ:LYRA) Stock Rating Reaffirmed by HC Wainwright - Defense World
Vanguard Group Inc. Raises Holdings in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Lyra Therapeutics Inc (LYRA) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
H.C. Wainwright holds Lyra Therapeutics stock at 'Neutral,' awaiting Phase 3 results - Investing.com Canada
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Given Average Rating of “Hold” by Brokerages - Defense World
LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Beats Revenue for Q2 2024 - MSN
Lyra Therapeutics Inc Stock (LYRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):